Pulmonary Hypertension: Why are we still going systemic?

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterised by remodelling of the small pulmonary arteries, leading to increased pulmonary vascular resistance (PVR) and ultimately right ventricular failure. The disease affects approximately 15 to 50 individuals per million, with a median survival that, despite advances, remains suboptimal. Patients typically present with dyspnoea, fatigue, and chest pain, often leading to significant delays in diagnosis. The underlying pathophysiology involves an imbalance of vasoconstrictors and vasodilators, alongside proliferative and anti-apoptotic processes within the pulmonary vasculature. Standard care has traditionally focused on targeting these pathways with oral, intravenous, or subcutaneous agents, but the systemic nature of these drugs often leads to dose-limiting side effects such as hypotension, flushing, and jaw pain.

Pulmonary hypertension associated with interstitial lung disease (PH-ILD) presents a distinct clinical challenge. Here, PH develops as a complication of underlying parenchymal lung disease, such as idiopathic pulmonary fibrosis (IPF) or connective tissue disease-associated ILD. The mechanisms contributing to PH in this context are complex, involving hypoxia-induced vasoconstriction, vascular remodelling, and fibrotic changes within the lung parenchyma. Management is complicated by the need to treat both the underlying ILD and the PH, with therapies for one often having detrimental effects on the other. The unmet need in both PAH and PH-ILD is substantial, particularly for treatments that can improve quality of life and long-term outcomes without exacerbating comorbidities or causing intolerable systemic adverse events.

The rationale for inhaled delivery

Inhaled therapies offer a direct route to the pulmonary circulation, bypassing systemic metabolism and reducing exposure to non-pulmonary tissues. This targeted delivery is particularly advantageous for agents that act as vasodilators, as it maximises their effect where it is needed most, in the pulmonary arteries, while minimising systemic hypotension and other off-target effects. The concept is not new; inhaled nitric oxide has been used in critical care settings for decades to selectively dilate pulmonary vessels. But the development of stable, deliverable formulations of other potent vasodilators has expanded the therapeutic possibilities for chronic management.

The primary class of inhaled agents in PH management are prostacyclin analogues. Prostacyclin (PGI2) is a potent vasodilator and inhibitor of platelet aggregation, and its deficiency is a key feature in PAH pathophysiology. Systemic prostacyclin analogues, administered intravenously or subcutaneously, are highly effective but carry a significant burden of side effects and complex administration. Inhaled formulations aim to retain the pulmonary selectivity of prostacyclin while improving tolerability and ease of use. These therapies are typically delivered via nebulisers, requiring patients to inhale the medication multiple times a day. This delivery method ensures that the drug reaches the alveolar-capillary membrane, where it can be absorbed into the pulmonary circulation and exert its local vasodilatory effects.

Established inhaled therapies and their mechanisms

Inhaled prostacyclin analogues work by activating prostacyclin receptors on pulmonary arterial smooth muscle cells, leading to an increase in intracellular cyclic AMP (cAMP). This rise in cAMP promotes smooth muscle relaxation and vasodilation, thereby reducing pulmonary vascular resistance and pulmonary arterial pressure. Beyond vasodilation, prostacyclins also possess anti-proliferative and anti-inflammatory properties, which may contribute to their long-term benefits in remodelling the pulmonary vasculature. The short half-life of these agents necessitates frequent dosing, typically 4 to 9 times daily, which can be a significant adherence challenge for patients.

Another class of inhaled therapies under investigation, though less established than prostacyclins, includes inhaled nitric oxide (iNO) and phosphodiesterase-5 (PDE5) inhibitors. While iNO is primarily used in acute settings, its potential for chronic use in select PH populations is being explored. PDE5 inhibitors, such as sildenafil and tadalafil, are mainstays of oral PAH therapy, but their systemic administration can lead to hypotension and other side effects. Inhaled formulations of PDE5 inhibitors aim to replicate the pulmonary selectivity seen with prostacyclins, though clinical development in this area has been more limited. The mechanism of PDE5 inhibitors involves preventing the breakdown of cyclic GMP (cGMP), another potent vasodilator, thereby enhancing the effects of endogenous nitric oxide.

The choice of nebuliser device is critical for effective drug delivery. Different devices have varying efficiencies in generating aerosol particles of the optimal size for deep lung penetration. Ultrasonic nebulisers and vibrating mesh nebulisers are often preferred over jet nebulisers due to their quieter operation, faster delivery times, and higher drug output efficiency. Patient education on proper nebuliser technique is paramount to ensure consistent and adequate drug delivery, as improper use can significantly reduce the amount of medication reaching the lungs. This practical aspect of care is often overlooked but directly impacts treatment efficacy.

Clinical utility in PAH and PH-ILD

In PAH, inhaled prostacyclin analogues are often used as add-on therapy for patients who remain symptomatic despite maximal oral therapy, or as a bridge to transplantation. They can improve exercise capacity, functional class, and haemodynamic parameters. The targeted delivery means that higher local concentrations can be achieved in the lungs compared to systemic administration, potentially leading to greater efficacy with fewer systemic side effects. This is particularly relevant for patients who experience significant hypotension or other adverse events with oral or intravenous agents. For a comprehensive overview of general medical practice, the Oxford Handbook of Clinical Medicine (11th ed) remains an invaluable resource.

The role of inhaled therapies in PH-ILD is still evolving. The complexity of PH-ILD, with its dual pathology of lung fibrosis and vascular remodelling, makes treatment decisions challenging. Systemic vasodilators can sometimes worsen gas exchange in PH-ILD by increasing perfusion to poorly ventilated areas of the lung, a phenomenon known as ventilation-perfusion mismatch. Inhaled vasodilators, by preferentially dilating vessels in better-ventilated lung regions, may theoretically mitigate this effect and improve gas exchange. This selective vasodilation is a key advantage, as it avoids the systemic effects that can be particularly problematic in patients with compromised lung function. Early data suggests that inhaled prostacyclins can improve haemodynamics and exercise capacity in select PH-ILD populations, but larger, definitive trials are needed to establish their long-term impact on survival and disease progression. The ongoing research into adaptive study programmes for pulmonary arterial hypertension highlights the continued efforts to refine treatment strategies.

But the practicalities of inhaled therapy cannot be ignored. The frequent dosing schedule and the need for nebuliser equipment can impact patient adherence and quality of life. Patients must be trained on proper nebuliser use and maintenance, and access to equipment and drug supplies must be ensured. The burden of therapy can be substantial, and this must be weighed against the potential benefits. Some patients find the time commitment and the need to carry equipment disruptive to their daily lives. Still, for those who cannot tolerate systemic therapies or who require additional pulmonary-specific vasodilation, the benefits often outweigh these challenges.

Adverse events and considerations

The main adverse events associated with inhaled prostacyclin analogues are typically local and related to the route of administration. These include cough, throat irritation, and bronchospasm. Systemic side effects, such as headache, flushing, and jaw pain, can still occur but are generally less severe and less frequent than with systemic formulations. The risk of hypotension is also reduced due to the targeted delivery. Careful titration of the dose is essential to minimise these side effects while achieving therapeutic benefit. Clinicians must monitor patients closely for any signs of worsening respiratory symptoms or paradoxical bronchoconstriction, especially in those with underlying reactive airway disease.

The long-term safety profile of these therapies is generally favourable, but the impact on right ventricular function and overall survival requires ongoing evaluation. While improvements in exercise capacity and haemodynamics are consistently observed, translating these into sustained improvements in hard clinical endpoints remains a focus of research. The complexity of PH, particularly in the context of ILD, means that a multi-pronged approach is often necessary, combining inhaled therapies with other targeted agents and supportive care. The advancements in NTM lung disease detection and therapy also underscore the broader efforts in respiratory medicine to improve patient outcomes.

The open-label nature of many early studies on inhaled therapies is an obvious caveat. While these studies provided valuable insights into safety and preliminary efficacy, the lack of blinding can introduce bias, particularly for subjective endpoints like dyspnoea and exercise tolerance. The trials were often not powered to detect differences in rare subgroups or long-term mortality, leaving gaps in our understanding of the full clinical impact. The heterogeneity of PH-ILD populations also complicates interpretation, as different underlying ILDs may respond differently to inhaled vasodilators. This highlights the need for more rigorously designed, adequately powered, and disease-specific trials to fully define the role of inhaled therapies.

The cost of inhaled prostacyclin analogues and the associated nebuliser equipment can be substantial, posing a barrier to access in some healthcare systems. This economic consideration must be balanced against the clinical benefits and the potential for reduced hospitalisations or improved quality of life. Payers and clinicians must work together to ensure that these valuable therapies are accessible to patients who stand to benefit most. The ongoing development of new formulations and delivery devices may help to address some of these challenges, potentially leading to more convenient and cost-effective options in the future. The field continues to explore novel targets and delivery methods, aiming to further refine treatment strategies for these complex conditions.